Gospel IL-6 inhibitors in patients with chronic kidney disease may reduce the risk of cardiovascular events

On May 17, 2021, at the 70th Annual Scientific Conference of the American College of Cardiology, Novo Nordisk announced the interleukin-6 (IL-6) inhibitor under investigation Phase 2 clinical trial results of ziltivekimab.

Cardiovascular disease is one of the diseases with the highest morbidity and mortality in the world.

Globally, approximately 700 million people suffer from chronic kidney disease.

Novo Nordisk acquired Corvidia Therapeutics for US$2.

RESCUE is a randomized, double-blind, placebo-controlled Phase 2 clinical trial with a total of 264 participants, and it aims to evaluate whether a monthly subcutaneous injection of ziltivekimab can help patients with advanced chronic kidney disease with elevated hsCRP It is safe and effective to reduce inflammation biomarkers.

Ziltivekimab reached the primary endpoint of the trial.

Note: The original text has been deleted

Reference materials:

[1] Ridker, PM, et, al.

[2] Ziltivekimab reduced inflammatory biomarkers associated with atherosclerosis in people with chronic kidney disease in phase 2 trial.

Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.